- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
52 result(s) found for: Oncogenic.
Displaying page 1 of 3.
EudraCT Number: 2009-017282-35 | Sponsor Protocol Number: 113617 | Start Date*: 2010-07-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects | ||
Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) NL (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008124-33 | Sponsor Protocol Number: 112024 | Start Date*: 2009-10-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn... | ||
Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006773-32 | Sponsor Protocol Number: HPV_CSP01 | Start Date*: 2009-05-20 | |||||||||||
Sponsor Name:Health Protection Agency | |||||||||||||
Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines | |||||||||||||
Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023831-40 | Sponsor Protocol Number: I124 | Start Date*: 2011-04-12 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO | |||||||||||||
Full Title: Study for metastatic thyroid cancer using 124i and [18F] FDG PET / CT in patients with elevated values of Tg and / or AbTg with negative ultrasonography of the neck, previously treated with thyroid... | |||||||||||||
Medical condition: Only patiens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002546-20 | Sponsor Protocol Number: 104820 | Start Date*: 2006-11-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly ac... | ||
Medical condition: For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormaliti... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004662-33 | Sponsor Protocol Number: C/39/2018 | Start Date*: 2019-07-12 |
Sponsor Name:Imperial College London | ||
Full Title: NOVEL: Nonavalent HPV vaccine after local conservative treatment for cervical pre-invasive disease - a randomised controlled trial | ||
Medical condition: Cervical intra-epithelial neoplasia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) SE (Ongoing) FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001325-14 | Sponsor Protocol Number: 580299/008 | Start Date*: 2004-08-12 |
Sponsor Name:GlaxoSmithKline SA | ||
Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit... | ||
Medical condition: cervical cancer => study is conducted in healthy female | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001731-55 | Sponsor Protocol Number: 106636 | Start Date*: 2007-08-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p... | |||||||||||||
Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001612-34 | Sponsor Protocol Number: GESIDA-7412 | Start Date*: 2013-02-18 |
Sponsor Name:Fundación SEIMC-GESIDA | ||
Full Title: A prostective, with one site, open-label not controled trial, for the observation of treatment with CIDOFOVIR 1%, 3 nights per week, during 4 weeks, of Anal Intraephitelial Neoplasia, high level, i... | ||
Medical condition: Intraephitelial Anal Neoplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001620-29 | Sponsor Protocol Number: R2-GDP-GOTEL | Start Date*: 2014-10-19 | |||||||||||
Sponsor Name:Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL) | |||||||||||||
Full Title: Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in patients diagnosed with refractory diffuse large B-cell lymph... | |||||||||||||
Medical condition: Refractory Diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000110-37 | Sponsor Protocol Number: PDT-DCF-1 | Start Date*: 2013-03-18 | |||||||||||
Sponsor Name:Fundacion para la investigación biomédica del hospital Ramón y Cajal de Madrid | |||||||||||||
Full Title: Clinical effectiveness and effect on COX-2 expression of the sequential treatment of actinic keratoses (AK) with photodynamic therapy (PDT) and diclofenac 3% gel: a phase IV clinical trial. | |||||||||||||
Medical condition: Actinic keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003098-26 | Sponsor Protocol Number: 3144A1-201-WW | Start Date*: 2006-06-06 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer | ||
Medical condition: Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004123-20 | Sponsor Protocol Number: UCL-ONCO2012-01 | Start Date*: 2013-03-11 |
Sponsor Name:Centre du Cancer, Cliniques universitaires Saint-Luc | ||
Full Title: A single arm, multicenter, phase II study of BEZ235 as monotherapy in patients with locally advanced or metastatic Transitional Cell Carcinoma (TCC) after failure of platinum based chemotherapy. | ||
Medical condition: To treat patients with histollogically- or cytologically-confirmed locally advanced or metastatic TCC not amenable to curative surgery or radiation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-005492-12 | Sponsor Protocol Number: BDTX-189-01 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:Black Diamond Therapeutics, Inc. | |||||||||||||
Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation... | |||||||||||||
Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004958-29 | Sponsor Protocol Number: CHUBX2019/25 | Start Date*: 2020-04-07 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020227-48 | Sponsor Protocol Number: 113618 | Start Date*: 2011-01-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1... | ||
Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000757-22 | Sponsor Protocol Number: 114700 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscu... | |||||||||||||
Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005943-24 | Sponsor Protocol Number: 580299/011 | Start Date*: 2006-03-29 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according t... | ||
Medical condition: In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001546-34 | Sponsor Protocol Number: EADO_VC_NEO_1 | Start Date*: 2014-10-02 | ||||||||||||||||
Sponsor Name:University Hospital Tübingen | ||||||||||||||||||
Full Title: Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single arm... | ||||||||||||||||||
Medical condition: Patients with hardly resectable/unresectable limited metastasis in malignant melanoma stages IIIC/IV (American Joint Committee on Cancer (AJCC) 2010) carrying the BRAF V600 mutation, in order to ac... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004390-41 | Sponsor Protocol Number: BLU-667-1101 | Start Date*: 2018-03-13 | ||||||||||||||||||||||||||
Sponsor Name:Blueprint Medicines | ||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Restarted) NL (Completed) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.